Skip to content
10-Q

Quarterly Report

Vincerx Pharma, Inc.

0001193125-25-120762

← back to feed
Filed
May 15, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 30, 2025 5.23M sh
Shares Diluted Q1 2025 · Mar 31, 2025 3.58K sh
Shares Diluted restated Q1 2025 · Mar 31, 2024 1.09K sh
Operating Cash Flow Q1 2025 · Mar 31, 2025 −$4.45M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$7.74M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $4.44M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $4.99M
Stockholders Equity Q1 2025 · Mar 31, 2025 $2.07M
Stockholders Equity Q1 2025 · Dec 31, 2024 $2.72M
Stockholders Equity Q1 2025 · Mar 31, 2024 −$622K
Stockholders Equity Q1 2025 · Dec 31, 2023 $11.22M
Current Liabilities Q1 2025 · Mar 31, 2025 $2.62M
Current Liabilities Q1 2025 · Dec 31, 2024 $5.28M
Total Liabilities Q1 2025 · Mar 31, 2025 $2.62M
Total Liabilities Q1 2025 · Dec 31, 2024 $5.28M
Current Assets Q1 2025 · Mar 31, 2025 $4.69M
Current Assets Q1 2025 · Dec 31, 2024 $6.41M
Total Assets Q1 2025 · Mar 31, 2025 $4.69M
Total Assets Q1 2025 · Dec 31, 2024 $8.01M
Eps Diluted Q1 2025 · Mar 31, 2025 −$1.40
Eps Diluted restated Q1 2025 · Mar 31, 2024 −$11.46
Eps Basic Q1 2025 · Mar 31, 2025 −$1.40
Eps Basic restated Q1 2025 · Mar 31, 2024 −$11.46
Sga Expense Q1 2025 · Mar 31, 2025 $2.32M
Sga Expense Q1 2025 · Mar 31, 2024 $2.92M
Net Income Q1 2025 · Mar 31, 2025 −$5M
Net Income Q1 2025 · Mar 31, 2024 −$12.43M
Operating Income Q1 2025 · Mar 31, 2025 −$3.33M
Operating Income Q1 2025 · Mar 31, 2024 −$7.48M